Regulatory tracker: Akeso's ivonescimab wins landmark first-line NSCLC nod in China

In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning.